OncoResponse, Inc.
OncoResponse is a biotech company focused on developing cancer immunotherapies by leveraging the human immune system, especially from elite responders to immunotherapy. They utilize proprietary platforms to discover and develop therapeutic antibodies targeting the tumor microenvironment, aiming to convert 'cold' tumors into 'hot' ones and improve treatment outcomes.
Industries
Nr. of Employees
small (1-50)
OncoResponse, Inc.
609 Main St, Suite 4200, Houston, TX 77002 United States
Patents
Products
Clinical‑stage anti‑CD163 monoclonal antibody (lead candidate)
A fully human monoclonal antibody derived from a patient elite responder that binds CD163 on tumor‑associated macrophages to relieve macrophage‑mediated immunosuppression; entered Phase 1/2 studies to assess safety, PK and preliminary activity alone and combined with anti‑PD‑1 therapy.
Pipeline of preclinical macrophage‑modulating antibodies
Multiple preclinical antibody programs targeting immunosuppressive myeloid/TAM pathways (including targets cited in presentations such as Siglec‑15, LILRB2 and EMP2‑directed programs) intended to relieve TME suppression and augment T‑cell activity.
Clinical‑stage anti‑CD163 monoclonal antibody (lead candidate)
A fully human monoclonal antibody derived from a patient elite responder that binds CD163 on tumor‑associated macrophages to relieve macrophage‑mediated immunosuppression; entered Phase 1/2 studies to assess safety, PK and preliminary activity alone and combined with anti‑PD‑1 therapy.
Pipeline of preclinical macrophage‑modulating antibodies
Multiple preclinical antibody programs targeting immunosuppressive myeloid/TAM pathways (including targets cited in presentations such as Siglec‑15, LILRB2 and EMP2‑directed programs) intended to relieve TME suppression and augment T‑cell activity.
Services
Joint programs to access patient biospecimens, clinical/genotypic data and translational expertise to support target identification and antibody discovery.
Outsourced execution of cell line development, process development and Phase I/II cGMP clinical manufacturing via an integrated CDMO partner.
Structuring of strategic alliances, collaborations and licensing or co‑development agreements to advance antibody programs.
Joint programs to access patient biospecimens, clinical/genotypic data and translational expertise to support target identification and antibody discovery.
Outsourced execution of cell line development, process development and Phase I/II cGMP clinical manufacturing via an integrated CDMO partner.
Structuring of strategic alliances, collaborations and licensing or co‑development agreements to advance antibody programs.
Expertise Areas
- Antibody discovery from human immune repertoires
- Tumor microenvironment modulation (myeloid/TAM biology)
- Preclinical immuno‑oncology development
- Early‑phase clinical trial management (Phase 1/2)
Key Technologies
- Immune repertoire screening (B‑cell discovery)
- Monoclonal antibody discovery and humanization
- Antibody engineering for macrophage targets
- In vitro macrophage functional assays
News & Updates
Clifford Stocks, CEO and Alice Bexon, CMO
Clifford Stocks, CEO and Chris Russell, CFO
Clifford Stocks, CEO
Clifford Stocks, CEO
Bob Lechleider, CMO and Chris Russell, CFO
Clifford Stocks, CEO
Clifford Stocks, CEO and Alice Bexon, CMO
Clifford Stocks, CEO and Chris Russell, CFO
Clifford Stocks, CEO
Clifford Stocks, CEO
Bob Lechleider, CMO and Chris Russell, CFO
Clifford Stocks, CEO